Wellnex Life Limited (ASX:WNX) has inked an exclusive distribution agreement with Homart Pharmaceuticals, facilitating the entry of Wellnex's brands into key Asian markets. The deal covers the distribution of all Wellnex brands, including the recently acquired Pain Away, capitalizing on the rising demand for top-tier Australian health and pharmaceutical products in Asia. Homart, with a robust distribution network spanning over 30 years, predominantly in China, Taiwan, and Vietnam, will bear all marketing and distribution costs, enhancing Wellnex's bottom line.
The Asia Pacific nutritional supplements market, valued at USD 149.4 Billion in 2022, is projected to surge to USD 240.6 Billion by 2030. The agreement is effective immediately, with Wellnex supplying products, including Pain Away, starting today. Wellnex anticipates substantial revenue growth and enhanced profitability through this strategic partnership.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
